Literature DB >> 24850740

Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes.

Elizabeth A White1, Johanna Walther2, Hassan Javanbakht2, Peter M Howley3.   

Abstract

UNLABELLED: The genus beta human papillomaviruses (beta HPVs) cause cutaneous lesions and are thought to be involved in the initiation of some nonmelanoma skin cancers (NMSCs), particularly in patients with the genetic disorder epidermodysplasia verruciformis (EV). We have previously reported that at least two of the genus beta HPV E6 proteins bind to and/or increase the steady-state levels of p53 in squamous epithelial cells. This is in contrast to a well-characterized ability of the E6 proteins of cancer-associated HPVs of genus alpha HPV, which inactivate p53 by targeting its ubiquitin-mediated proteolysis. In this study, we have investigated the ability of genus beta E6 proteins from eight different HPV types to block the transactivation of p53 target genes following DNA damage. We find that the E6 proteins from diverse beta HPV species and types vary in their capacity to block the induction of MDM2, p21, and proapoptotic genes after genotoxic stress. We conclude that some genus beta HPV E6 proteins inhibit at least some p53 target genes, although perhaps not by the same mechanism or to the same degree as the high-risk genus alpha HPV E6 proteins. IMPORTANCE: This study addresses the ability of various human papillomavirus E6 proteins to block the activation of p53-responsive cellular genes following DNA damage in human keratinocytes, the normal host cell for HPVs. The E6 proteins encoded by the high-risk, cancer-associated HPV types of genus alpha HPV have a well-established activity to target p53 degradation and thereby inhibit the response to DNA damage. In this study, we have investigated the ability of genus beta HPV E6 proteins from eight different HPV types to block the ability of p53 to transactivate downstream genes following DNA damage. We find that some, but not all, genus beta HPV E6 proteins can block the transactivation of some p53 target genes. This differential response to DNA damage furthers the understanding of cutaneous HPV biology and may help to explain the potential connection between some beta HPVs and cancer.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24850740      PMCID: PMC4135955          DOI: 10.1128/JVI.01197-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.

Authors:  A Ito; C H Lai; X Zhao; S Saito; M H Hamilton; E Appella; T P Yao
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

2.  Cutaneous β-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling.

Authors:  Min Jie Alvin Tan; Elizabeth A White; Mathew E Sowa; J Wade Harper; Jon C Aster; Peter M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

3.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

4.  Modulation of TGF-β-inducible hypermotility by EGF and other factors in human prostate epithelial cells and keratinocytes.

Authors:  Wei Wei; Patricia D Barron; James G Rheinwald
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-11-02       Impact factor: 2.416

5.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes.

Authors:  K Münger; W C Phelps; V Bubb; P M Howley; R Schlegel
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins.

Authors:  S Jackson; C Harwood; M Thomas; L Banks; A Storey
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

Review 7.  The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity.

Authors:  M Tomasz; Y Palom
Journal:  Pharmacol Ther       Date:  1997 Oct-Dec       Impact factor: 12.310

8.  Small internal deletions in the human cytomegalovirus IE2 gene result in nonviable recombinant viruses with differential defects in viral gene expression.

Authors:  Elizabeth A White; Charles L Clark; Veronica Sanchez; Deborah H Spector
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Beta human papillomavirus E6 expression inhibits stabilization of p53 and increases tolerance of genomic instability.

Authors:  Nicholas A Wallace; Kristin Robinson; Denise A Galloway
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

10.  Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2.

Authors:  Dorothea Muschik; Ilona Braspenning-Wesch; Eggert Stockfleth; Frank Rösl; Thomas G Hofmann; Ingo Nindl
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

View more
  18 in total

Review 1.  Beta genus papillomaviruses and skin cancer.

Authors:  Peter M Howley; Herbert J Pfister
Journal:  Virology       Date:  2015-02-24       Impact factor: 3.616

2.  Proteomic analysis of the gamma human papillomavirus type 197 E6 and E7 associated cellular proteins.

Authors:  Miranda Grace; Karl Munger
Journal:  Virology       Date:  2016-10-20       Impact factor: 3.616

Review 3.  HPV vaccination for prevention of skin cancer.

Authors:  Sabrina E Vinzón; Frank Rösl
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  The Human Papillomavirus E6 Oncoprotein Targets USP15 and TRIM25 To Suppress RIG-I-Mediated Innate Immune Signaling.

Authors:  Cindy Chiang; Eva-Katharina Pauli; Jennifer Biryukov; Katharina F Feister; Melissa Meng; Elizabeth A White; Karl Münger; Peter M Howley; Craig Meyers; Michaela U Gack
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

5.  Detection of human papillomaviruses in paired healthy skin and actinic keratosis by next generation sequencing.

Authors:  Luisa Galati; Rosario Nicola Brancaccio; Alexis Robitaille; Cyrille Cuenin; Fabiola Luzi; Gianna Fiorucci; Maria Vincenza Chiantore; Nadia Marascio; Giovanni Matera; Maria Carla Liberto; Maria Gabriella Donà; Paola Di Bonito; Tarik Gheit; Massimo Tommasino
Journal:  Papillomavirus Res       Date:  2020-03-25

6.  Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.

Authors:  Valdimara C Vieira; Brandon Leonard; Elizabeth A White; Gabriel J Starrett; Nuri A Temiz; Laurel D Lorenz; Denis Lee; Marcelo A Soares; Paul F Lambert; Peter M Howley; Reuben S Harris
Journal:  mBio       Date:  2014-12-23       Impact factor: 7.867

7.  Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment.

Authors:  Juan Carlos Higareda-Almaraz; Juan S Ruiz-Moreno; Jana Klimentova; Daniela Barbieri; Raquel Salvador-Gallego; Regina Ly; Ilse A Valtierra-Gutierrez; Christiane Dinsart; Gabriel A Rabinovich; Jiri Stulik; Frank Rösl; Bladimiro Rincon-Orozco
Journal:  BMC Cancer       Date:  2016-08-24       Impact factor: 4.430

Review 8.  Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients.

Authors:  Ramya Chockalingam; Christopher Downing; Stephen K Tyring
Journal:  J Clin Med       Date:  2015-06-03       Impact factor: 4.241

9.  Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells.

Authors:  Anja Honegger; Daniela Schilling; Sandra Bastian; Jasmin Sponagel; Vladimir Kuryshev; Holger Sültmann; Martin Scheffner; Karin Hoppe-Seyler; Felix Hoppe-Seyler
Journal:  PLoS Pathog       Date:  2015-03-11       Impact factor: 6.823

10.  High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation.

Authors:  Elizabeth A White; Karl Münger; Peter M Howley
Journal:  mBio       Date:  2016-09-20       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.